The Smith-Kettlewell Eye Research Institute scientist developed Botox for medicinal use.

As Omicron induces a sense of deja vu at the close of the year, we look back at a few key ways in which our understanding has moved forward.

Author Lauren Aguirre finds reasons for optimism in the fight against Alzheimer’s disease.

The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.

The midwestern state has quietly laid the groundwork for a biotech hub.

The East Coast campus of the research institute received shipments of freeze-dried or frozen samples of more than 210,000 microbial strains, which scientists plan to mine for potentially useful natural products.

The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.

Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.

Decades after their discovery by bioprospectors, amphibian-derived analgesics continue to attract scientific attention.

Studying cone snail venom has yielded novel pain pathways, but the peptides that function as toxins are difficult to translate into drugs.

Venomous centipedes may harbor a clue to the creation of a successful pain-killing compound for humans.

Arachnids harbor a plentiful array of molecules that target mammalian pain receptors.

In tiny doses, the pufferfish’s tetrodotoxin can be turned into a pain-relieving ion channel blocker.